Swedbank AB trimmed its holdings in shares of Natera, Inc. (NASDAQ:NTRA – Free Report) by 5.5% in the 1st quarter, Holdings Channel.com reports. The institutional investor owned 45,534 shares of the medical research company’s stock after selling 2,650 shares during the period. Swedbank AB’s holdings in Natera were worth $9,106,000 at the end of the most recent reporting period.
A number of other institutional investors have also added to or reduced their stakes in the business. Whittier Trust Co. of Nevada Inc. grew its holdings in shares of Natera by 85.8% during the first quarter. Whittier Trust Co. of Nevada Inc. now owns 275 shares of the medical research company’s stock worth $56,000 after purchasing an additional 127 shares in the last quarter. Ascentis Independent Advisors bought a new stake in Natera during the first quarter valued at approximately $111,000. Praxis Investment Management Inc. grew its stake in Natera by 5.0% in the 1st quarter. Praxis Investment Management Inc. now owns 3,800 shares of the medical research company’s stock worth $760,000 after buying an additional 180 shares in the last quarter. QRG Capital Management Inc. grew its stake in Natera by 17.5% in the 1st quarter. QRG Capital Management Inc. now owns 14,691 shares of the medical research company’s stock worth $2,938,000 after buying an additional 2,184 shares in the last quarter. Finally, HB Wealth Management LLC increased its holdings in shares of Natera by 11.0% in the 1st quarter. HB Wealth Management LLC now owns 3,076 shares of the medical research company’s stock worth $615,000 after buying an additional 304 shares during the last quarter. 99.90% of the stock is currently owned by institutional investors.
Insider Buying and Selling
In related news, insider Solomon Moshkevich sold 3,000 shares of the stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $272.90, for a total transaction of $818,700.00. Following the completion of the sale, the insider directly owned 134,643 shares in the company, valued at $36,744,074.70. This represents a 2.18% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Herm Rosenman sold 16,530 shares of the firm’s stock in a transaction that occurred on Wednesday, June 24th. The stock was sold at an average price of $250.00, for a total value of $4,132,500.00. Following the transaction, the director owned 4,250 shares in the company, valued at approximately $1,062,500. The trade was a 79.55% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 178,872 shares of company stock worth $39,627,696 in the last 90 days. 5.05% of the stock is currently owned by company insiders.
Natera Price Performance
Analysts Set New Price Targets
Several research firms have recently weighed in on NTRA. Morgan Stanley raised their price objective on shares of Natera from $250.00 to $310.00 and gave the company an “overweight” rating in a research report on Thursday. Barclays reduced their target price on Natera from $280.00 to $260.00 and set an “overweight” rating on the stock in a research note on Wednesday, June 24th. Wall Street Zen downgraded Natera from a “buy” rating to a “hold” rating in a research report on Saturday, May 9th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Natera in a research note on Tuesday, April 21st. Finally, Robert W. Baird set a $265.00 price objective on Natera in a report on Friday, May 8th. Three analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $265.33.
Read Our Latest Stock Analysis on Natera
About Natera
Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.
Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.
Recommended Stories
- Five stocks we like better than Natera
- Power Struggle: Wolfspeed Sues Navitas Over AI Chips
- Why WD-40 Is Proving Great Businesses Never Go Out of Style
- Pushing the Edge: Super Micro Computer Reboots the AI Landscape
- MarketBeat Week in Review – 07/06 – 07/10
Want to see what other hedge funds are holding NTRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natera, Inc. (NASDAQ:NTRA – Free Report).
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.
